Sodium glucose transport-2 (SGLT-2) inhibitors, which reduce glucose reabsorption by the kidneys, can help control blood sugar levels and protect kidney health in patients with diabetic kidney disease; however, some large clinical trials have linked the medications to a higher risk of bone fractures. In a recent study published in Journal of the American Society of Nephrology, SGLT-2 inhibitors were not associated with a higher risk of fractures when compared with another diabetes medication, regardless of patients’ kidney function.